Galderma presented new three-year Nemluvio® data at Fall Clinical 2026, reporting deep and lasting responses in both skin lesions and itch in patients with atopic dermatitis aged 12 and older.

The dataset extends the follow-up period for the interleukin-31 receptor antagonist to a full three years, positioning Nemluvio among the longer-characterized biologic options for adolescent and adult atopic dermatitis. Galderma framed the results as evidence that the depth of lesion clearance and itch relief seen in earlier trials holds up over sustained real-world-equivalent exposure.

What does the new dataset cover?

The presentation focuses on two of the endpoints clinicians weigh most heavily in atopic dermatitis: skin lesion response and itch response. Atopic dermatitis trials typically quantify lesion severity through EASI (Eczema Area and Severity Index) scoring and itch through validated patient-reported intensity measures; the source material does not break out specific scores from the Fall Clinical 2026 presentation, so the headline finding rests on Galderma's characterization of responses as both "deep" and "lasting" across the three-year window.

The age range matters for practice. Data covering patients aged 12 and older speak directly to the adolescent cohort, where treatment decisions often balance efficacy, long-term safety and the burden of chronic immunomodulation.

Why is a three-year timeframe significant?

Atopic dermatitis is a chronic, relapsing disease, and payers and prescribers increasingly demand durability evidence rather than 16-week pivotal endpoints. A three-year dataset allows clinicians to counsel patients on what sustained therapy with Nemluvio can realistically deliver in terms of lesion control and itch suppression.

Itch, in particular, drives sleep disruption and quality-of-life impairment in atopic dermatitis. A treatment showing durable itch response over three years addresses the symptom patients rank as most bothersome, not just visible lesion counts.

Manufacturer claims versus trial data

The results come from Galderma itself, presented at the Fall Clinical 2026 congress. As with any company-sponsored data release, the depth and durability language reflects Galderma's interpretation of its own dataset; peer-reviewed publication and independent analysis will determine how the findings translate into comparative positioning against other biologics and systemic agents in the atopic dermatitis armamentarium.

Clinicians attending Fall Clinical 2026 or reviewing the congress materials will want to watch for the full responder-level figures, discontinuation rates and safety events that a headline release does not always enumerate.

What comes next

Galderma will likely pair the Fall Clinical presentation with submission to a peer-reviewed journal, and the three-year durability data could strengthen the case for Nemluvio in formulary discussions and treatment guidelines for moderate-to-severe atopic dermatitis in patients aged 12 and older.